Last reviewed · How we verify
Risperdal
At a glance
| Generic name | Risperdal |
|---|---|
| Also known as | risperidone, Risperidone |
| Sponsor | Ohio State University |
| Target | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Bipolar affective disorder, current episode manic
- Bipolar disorder in remission
- Infantile autism
- Mixed bipolar I disorder
- Schizophrenia
Common side effects
- Parkinsonism
- Akathisia
- Dystonia
- Tremor
- Sedation
- Dizziness
- Anxiety
- Blurred vision
- Nausea
- Vomiting
- Upper abdominal pain
- Stomach discomfort
Serious adverse events
- Somnolence
- Rash
- Nasal congestion
- Upper respiratory tract infection
- Nasopharyngitis
- Pharyngolaryngeal pain
Key clinical trials
- Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects (PHASE1)
- Subjective Experience Following Psilocybin (PHASE2)
- CLOZAPINE Response in Biotype-1 (PHASE4)
- National Pregnancy Registry for Psychiatric Medications
- "Extended" (Alternate Day) Antipsychotic Dosing (PHASE4)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome (NA)
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |